Spoken language outcome measures for treatment studies in Down syndrome: feasibility, practice effects, test-retest reliability, and construct validity of variables generated from expressive language sampling.


Journal

Journal of neurodevelopmental disorders
ISSN: 1866-1955
Titre abrégé: J Neurodev Disord
Pays: England
ID NLM: 101483832

Informations de publication

Date de publication:
08 04 2021
Historique:
received: 23 11 2020
accepted: 17 03 2021
entrez: 8 4 2021
pubmed: 9 4 2021
medline: 27 8 2021
Statut: epublish

Résumé

The purpose of this study was to evaluate expressive language sampling (ELS) as a procedure for generating spoken language outcome measures for treatment research in Down syndrome (DS). We addressed (a) feasibility, (b) practice effects across two short-term administrations, (c) test-retest reliability across two short-term administrations, (d) convergent and discriminant construct validity, and (e) considered comparisons across the conversation and narration contexts. Participants were 107 individuals with DS between 6 and 23 years of age who presented with intellectual disability (IQ < 70). The utility of ELS procedures designed to collect samples of spoken language in conversation and narration were evaluated separately. Variables of talkativeness, vocabulary, syntax, utterance planning, and articulation quality, derived from transcripts segmented into C-units (i.e., an independent clause and its modifiers), were considered. A 4-week interval was used to assess practice effects and test-retest reliability. Standardized direct assessments and informant report measures were collected to evaluate construct validity of the ELS variables. Low rates of noncompliance were observed; youth who were under 12 years of age, had phrase-level speech or less, and had a 4-year-old developmental level or less were at particular risk for experiencing difficulty completing the ELS procedures. Minimal practice effects and strong test-retest reliability across the 4-week test-retest interval was observed. The vocabulary, syntax, and speech intelligibility variables demonstrated strong convergent and discriminant validity. Although significant correlations were found between the variables derived from both the conversation and narration contexts, some differences were noted. The ELS procedures considered were feasible and yielded variables with adequate psychometric properties for most individuals with DS between 6 and 23 years old. That said, studies of outcome measures appropriate for individuals with DS with more limited spoken language skills are needed. Context differences were observed in ELS variables suggest that comprehensive evaluation of expressive language is likely best obtained when utilizing both contexts.

Sections du résumé

BACKGROUND
The purpose of this study was to evaluate expressive language sampling (ELS) as a procedure for generating spoken language outcome measures for treatment research in Down syndrome (DS). We addressed (a) feasibility, (b) practice effects across two short-term administrations, (c) test-retest reliability across two short-term administrations, (d) convergent and discriminant construct validity, and (e) considered comparisons across the conversation and narration contexts.
METHOD
Participants were 107 individuals with DS between 6 and 23 years of age who presented with intellectual disability (IQ < 70). The utility of ELS procedures designed to collect samples of spoken language in conversation and narration were evaluated separately. Variables of talkativeness, vocabulary, syntax, utterance planning, and articulation quality, derived from transcripts segmented into C-units (i.e., an independent clause and its modifiers), were considered. A 4-week interval was used to assess practice effects and test-retest reliability. Standardized direct assessments and informant report measures were collected to evaluate construct validity of the ELS variables.
RESULTS
Low rates of noncompliance were observed; youth who were under 12 years of age, had phrase-level speech or less, and had a 4-year-old developmental level or less were at particular risk for experiencing difficulty completing the ELS procedures. Minimal practice effects and strong test-retest reliability across the 4-week test-retest interval was observed. The vocabulary, syntax, and speech intelligibility variables demonstrated strong convergent and discriminant validity. Although significant correlations were found between the variables derived from both the conversation and narration contexts, some differences were noted.
CONCLUSION
The ELS procedures considered were feasible and yielded variables with adequate psychometric properties for most individuals with DS between 6 and 23 years old. That said, studies of outcome measures appropriate for individuals with DS with more limited spoken language skills are needed. Context differences were observed in ELS variables suggest that comprehensive evaluation of expressive language is likely best obtained when utilizing both contexts.

Identifiants

pubmed: 33827417
doi: 10.1186/s11689-021-09361-6
pii: 10.1186/s11689-021-09361-6
pmc: PMC8028777
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

13

Subventions

Organisme : NICHD NIH HHS
ID : R01 HD074346
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD079125
Pays : United States
Organisme : National Institute of Child Health and Human Development
ID : R01HD074346
Organisme : NCATS NIH HHS
ID : UL1 TR001860
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000002
Pays : United States
Organisme : NICHD NIH HHS
ID : P50 HD103526
Pays : United States
Organisme : National Institute of Child Health and Human Development
ID : P50HD103526

Références

Front Behav Neurosci. 2015 Oct 06;9:265
pubmed: 26500515
J Neurodev Disord. 2017 Jun 12;9:7
pubmed: 28616096
J Speech Lang Hear Res. 2006 Apr;49(2):325-37
pubmed: 16671847
J Pediatr Health Care. 2006 May-Jun;20(3):198-205
pubmed: 16675381
J Intellect Disabil Res. 2010 Mar;54(3):246-65
pubmed: 20146742
Downs Syndr Res Pract. 2006 Jul;10(2):61-6
pubmed: 16869363
Am J Speech Lang Pathol. 2018 Feb 6;27(1):123-135
pubmed: 29222570
Front Genet. 2018 Oct 01;9:424
pubmed: 30327664
Acta Neuropsychol. 2004;2(1):70-85
pubmed: 29213294
J Neurodev Disord. 2009 Mar;1(1):33-45
pubmed: 19865612
J Speech Lang Hear Res. 2010 Oct;53(5):1334-48
pubmed: 20643789
Neurology. 2020 Mar 24;94(12):e1229-e1240
pubmed: 32094241
J Neurodev Disord. 2014;6(1):16
pubmed: 26491488
Am J Ment Defic. 1985 Mar;89(5):485-91
pubmed: 3993694
Ment Retard. 1995 Oct;33(5):279-88
pubmed: 7476250
J Commun Disord. 2020 May - Jun;85:105992
pubmed: 32445828
Autism Res. 2021 Jan;14(1):112-126
pubmed: 32909382
J Child Lang. 2013 Jan;40(1):244-65
pubmed: 23217297
J Dev Behav Pediatr. 2013 Sep;34(7):508-22
pubmed: 24042082
J Speech Lang Hear Res. 2009 Jun;52(3):643-52
pubmed: 19380608
Semin Speech Lang. 2016 Nov;37(4):239-251
pubmed: 27701700
Nat Rev Drug Discov. 2018 Apr;17(4):280-299
pubmed: 29217836
J Neurodev Disord. 2020 Mar 24;12(1):10
pubmed: 32204695
Ment Retard Dev Disabil Res Rev. 2007;13(3):262-71
pubmed: 17910079
Lang Speech Hear Serv Sch. 2010 Oct;41(4):393-404
pubmed: 20601531
J Speech Lang Hear Res. 2019 Jan 22;63(1):274-285
pubmed: 31944883
J Autism Dev Disord. 2020 Jul;50(7):2287-2306
pubmed: 29873016
Drug Des Devel Ther. 2014 Dec 17;9:103-25
pubmed: 25552901
J Pediatr. 2013 Oct;163(4):1163-8
pubmed: 23885965
Am J Intellect Dev Disabil. 2017 May;122(3):247-281
pubmed: 28452584
J Child Lang. 2006 Feb;33(1):125-44
pubmed: 16566323
J Speech Lang Hear Res. 2012 Aug;55(4):1022-38
pubmed: 22232386
Am J Med Genet A. 2017 Nov;173(11):3029-3041
pubmed: 28884975

Auteurs

Angela John Thurman (AJ)

MIND Institute, University of California Davis Health, 2825 50th Street, Sacramento, CA, USA. ajthurman@ucdavis.edu.
Department of Psychiatry and Behavioral Sciences, University of California Davis Health, Sacramento, CA, USA. ajthurman@ucdavis.edu.

Jamie O Edgin (JO)

Department of Psychology, University of Arizona, Tucson, AZ, USA.

Stephanie L Sherman (SL)

Department of Human Genetics, Emory University, Atlanta, GA, USA.

Audra Sterling (A)

Waisman Center and Department of Communication Sciences and Disorders, University of Wisconsin-Madison, Madison, WI, USA.

Andrea McDuffie (A)

MIND Institute, University of California Davis Health, 2825 50th Street, Sacramento, CA, USA.
Department of Psychiatry and Behavioral Sciences, University of California Davis Health, Sacramento, CA, USA.

Elizabeth Berry-Kravis (E)

Departments of Pediatrics, Neurological Sciences and Biochemistry, Rush University Medical Center, Chicago, IL, USA.

Debra Hamilton (D)

Department of Human Genetics, Emory University, Atlanta, GA, USA.

Leonard Abbeduto (L)

MIND Institute, University of California Davis Health, 2825 50th Street, Sacramento, CA, USA.
Department of Psychiatry and Behavioral Sciences, University of California Davis Health, Sacramento, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH